articleThe Lancet OncologyApr 5, 2015Closed access

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

AMAlexander M.M. EggermontVCVanna Chiarion‐SileniJGJean‐Jacques GrobRDReinhard DummerJDJedd D. Wolchok

Institut Gustave Roussy · Istituto Oncologico Veneto · +22 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,252
total citations
FWCI
72.30
Percentile
100%
References
24
Citations per year

Authors

22

Topics & keywords

Topics
Keywords
  • Ipilimumab
  • Placebo
  • Medicine
  • Adjuvant
  • Oncology
  • Melanoma
  • Internal medicine
  • Stage (stratigraphy)
No related works found for this paper.

Funding